International pharmaceutical company, Pfizer, has announced a move to end all early-stage projects in neuroscience.
The decision, announced last weekend, will see an end to further research into neurological conditions, such as Parkinson's and Alzheimer's, from one of the world's largest pharmaceutical companies.
It follows a routine review of R&D operations at the firm, which will see Pfizer concentrate on areas where they have stronger scientific leadership.
Dr Arthur Roach, Director of Research, comments on the announcement:
"While we are disappointed by Pfizer's announcement, Parkinson's UK will continue to work with urgency and determination in partnership with other pharmaceutical companies to create and develop new treatments on behalf of people with Parkinson's everywhere.
"We know, from our work with pharmaceutical companies across the globe, that there are many others still ready to devote tremendous time, effort and funding towards the development of better treatments for Parkinson's.
"For instance, our tireless work with the nine pharmaceutical companies who are members of our Critical Path for Parkinson’s consortium is helping smooth the path for all future drugs by making clinical trials smarter and faster.
"Pharmaceutical companies regularly review their research efforts and spend in different areas and moves like this are not uncommon. That does not shake Parkinson's UK's commitment to research that will bring forward the day when no one fears Parkinson's."